Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
DE000A1EWVY8
Wed, 13.08.2025
Formycon AG
Press Release // August 13, 2025
Formycon confirms full-year guidance following business development in line with plan – working capital raised
Half-year results in line with expectations – full-year 2025 guidance confirmed
Outlook for working capital raised following successful placement of oversubscribed €70 million corporate bond
Strong se [ … ]
Mon, 04.08.2025
Formycon AG
Company Name:
Formycon AG
ISIN:
DE000A1EWVY8
Reason for the research:
Update
Recommendation:
Buy
from:
04.08.2025
Target price:
€49
Target price on sight of:
12 months
Last rating change:
-
Analyst:
Simon Scholes
First Berlin Equity Research has published a research update on Formycon AG (ISIN: DE000A1EWVY8). Analyst Simo [ … ]
Wed, 30.07.2025
Formycon AG
Press Release // July 30, 2025
Formycon invites to conference call on 2025 half-year results and announces participation in international investor conferences in the 3rd quarter of 2025
Planegg-Martinsried, Germany – Formycon AG (FSB: FYB, Prime Standard, „Formycon“) plans to publish its results of the first half of the 2025 fiscal year on Au [ … ]
Thu, 10.07.2025
Formycon AG
Press Release // July 10, 2025
Formycon successfully completes patient enrollment for the clinical development of its Keytruda® biosimilar candidate FYB206
Streamlined clinical development program, which no longer requires a Phase III trial, is already in a far advanced stage
Last patient enrolled in Dahlia pharmacokinetic (PK) study (Last P [ … ]
Tue, 01.07.2025
Formycon AG
Press Release // July 1, 2025
Bio Usawa becomes partner for the commercialization of FYB201/ BioUcenta™ (ranibizumab) across Sub-Saharan Africa
Partnership marks a landmark step towards global availability of FYB201
Bio Usawa gets exclusive rights to register and commercialize FYB201/BioUcenta™1 in Sub-Saharan Africa
Product launch expected in [ … ]
Fri, 27.06.2025
Formycon AG
Press Release // 27. June 2025
Formycon increases bond volume following oversubscription – Bond 2025/2029 with a volume of EUR 70 million successfully and entirely placed
Due to strong demand, the offering period for the public offering has been shortened and target volume was increased from initially EUR 50 million to EUR 70 million
Interest [ … ]
Fri, 27.06.2025
Formycon AG
Disclosure of Inside Information Pursuant to Article 17 of Regulation (EU) No. 596/2014
NOT FOR DISTRIBUTION, PUBLICATION OR TRANSMISSION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION OR PUBLICATION MAY BE UNLAWFUL. FURTHER RESTRICTIONS APPLY. PLEASE [ … ]
Thu, 26.06.2025
Formycon AG
Press Release // June 26, 2025
Teva becomes secondary commercialization partner for Formycon's Stelara® biosimilar FYB202 (ustekinumab) under the brand name Fymskina® in Germany
Teva's subsidiary Ratiopharm is going to commercialize Fymskina® as a second Formycon ustekinumab biosimilar on a semi-exclusive basis in Germany
Market launch of F [ … ]
Wed, 25.06.2025
Formycon AG
Press Release // June 25, 2025
U.S. biosimilar specialist Valorum Biologics LLC becomes commercialization partner for Formycon’s Eylea® biosimilar FYB203/AHZANTIVE® (aflibercept-mrbb) in the United States and Canada
Valorum Biologics, an expert for ophthalmology and oncology biosimilars in the U.S. market, will exclusively commercialize FYB20 [ … ]
Tue, 24.06.2025
Formycon AG
Press Release // June 24, 2025
Strong demand for Formycon 2025/2029 Bond leads to early closing of subscription period
High demand by institutional investors enables early termination of public offering period
Subscription period via the Formycon website is now scheduled to end on 26 June 2025, at 11:59 p.m. CEST
Subscription via Deutsche B [ … ]
